Argenica Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Liz Dallimore

Chief executive officer

AU$675.0k

Total compensation

CEO salary percentage	37.0%
CEO tenure	2.1yrs
CEO ownership	0.04%
Management average tenure	no data
Board average tenure	2.1yrs

Recent management updates

Recent updates

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Jan 12

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Aug 12

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Apr 29

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Dec 30

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Sep 16

CEO Compensation Analysis

How has Liz Dallimore's remuneration changed compared to Argenica Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-AU$5m
Sep 30 2023	n/a	n/a	-AU$5m
Jun 30 2023	AU$675k	AU$250k	-AU$5m
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$4m
Sep 30 2022	n/a	n/a	-AU$4m
Jun 30 2022	AU$337k	AU$228k	-AU$4m
Mar 31 2022	n/a	n/a	-AU$3m
Dec 31 2021	n/a	n/a	-AU$3m
Sep 30 2021	n/a	n/a	-AU$2m
Jun 30 2021	AU$145k	AU$31k	-AU$1m

Compensation vs Market: Liz's total compensation ($USD446.02K) is above average for companies of similar size in the Australian market ($USD297.80K).

Compensation vs Earnings: Liz's compensation has increased whilst the company is unprofitable.

CEO

Liz Dallimore

2.1yrs

Tenure

AU$674,955

Compensation

Dr. Liz Dallimore (B. Sc. (Hons), MBA, PhD, GAICD) serves as Chief Executive Officer of Argenica Therapeutics Limited ands serves as its Managing Director and Director since April 4, 2022. She is a researc...

Board Members

Name	Position	Tenure	Compensation	Ownership
Liz Dallimore	CEO, MD & Director	2.1yrs	AU$674.96k	0.041% A$ 29.7k
Dianne Angus	Non-Executive Chairman	less than a year	no data	no data
Geoffrey Donnan	Member of Clinical Advisory Committee	no data	no data	no data
Terence Budge	Independent Non-Executive Director	3.3yrs	AU$36.90k	0.40% A$ 290.1k
Elizabeth McCall	Independent Non-Executive Director	3.4yrs	AU$36.90k	0.10% A$ 74.4k
Geoffrey Richard Pocock	Non-Executive Director	no data	AU$83.31k	3.61% A$ 2.6m
Paul Bailey	Member of Clinical Advisory Committee	no data	no data	no data
Tim Phillips	Member of Clinical Advisory Committee	no data	no data	no data
David Blacker	Chairman of Clinical Advisory Committee	no data	no data	no data
Jeffery Saver	Member of Clinical Advisory Committee	1.8yrs	no data	no data

2.1yrs

Average Tenure

Experienced Board: AGN's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Argenica Therapeutics Management

Management criteria checks 0/4

Key information

Recent management updates

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 24, 2022

Argenica Therapeutics Limited Appoints Dr. Jeffery Saver to Clinical Advisory Committee

Less than half of directors are independent

Recent updates

Argenica Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics Limited Announces Preclinical Data Shows ARG-007 Inhibits A Cause of Alzheimers

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Approves Commencement of Fourth and Final Cohort Dosing

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics Limited Announces That the First Subjects in the Third Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Dosed

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee (SRC) to Progress to the Third Escalated Dose Cohort

Less than half of directors are independent

Argenica Therapeutics Limited Announces Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee to Progress to the Second Escalated Dose Cohort

Argenica Therapeutics Limited Announces Healthy Participants in the First Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Successfully Dosed, Indicating Good Safety and Tolerability of ARG-007 in These Participants

Argenica Therapeutics Limited Announces First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

Argenica Therapeutics Limited Announces Further Positive Preclinical Results for ARG-007 in Hypoxic-Ischaemic Encephalopathy

Argenica Therapeutics Limited, Annual General Meeting, Nov 24, 2022

Argenica Therapeutics Limited Announces Phase 1 Clinical Trial Summary

Argenica Therapeutics Limited Receives Ethics Approval to Commence Phase 1 Trial

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Argenica Therapeutics Limited Submits Application to Seek Approval to Commence Phase 1 Healthy Participant Study of ARG-007

Argenica Therapeutics Limited Appoints Dr. Jeffery Saver to Clinical Advisory Committee

Argenica Therapeutics Limited Announces Completion of the Final Pharmacokinetic (PK) Study of ARG-007 Required for the Phase 1 Clinical Trial

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Argenica Therapeutics Limited Announces Results of In-Life Rodent and Non-Human Primate Toxicology Studies Which Have Established the Maximum Tolerated Dose (MTD) of ARG-007

Less than half of directors are independent

Less than half of directors are independent

Argenica Therapeutics Limited Announces Management Changes

Argenica Therapeutics Limited Announces Positive Preclincal Data on Efficacy of ARG-007

Argenica Therapeutics Limited Announces Successful Completion of Final GLP Genotoxicity Studies

Argenica Therapeutics Announces Completion of Preliminary Pre-Clinical Tox Studies

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics Limited Provides Additional Information of Study Shows ARG-007 Does Not Degrade

Argenica Therapeutics Limited Provides Positive Preliminary for ARG-007

Argenica Therapeutics Limited Completes Pilot Pre-Clinical Pharmacokinetics Study

Argenica Therapeutics Limited has completed an IPO in the amount of AUD 7 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure